Literature DB >> 23494494

Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study.

Flavie Bratan1, Emilie Niaf, Christelle Melodelima, Anne Laure Chesnais, Rémi Souchon, Florence Mège-Lechevallier, Marc Colombel, Olivier Rouvière.   

Abstract

OBJECTIVES: To assess factors influencing prostate cancer detection on multiparametric (T2-weighted, diffusion-weighted, and dynamic contrast-enhanced) MRI.
METHODS: One hundred and seventy-five patients who underwent radical prostatectomy were included. Pre-operative MRI performed at 1.5 T (n = 71) or 3 T (n = 104), with (n = 58) or without (n = 117) an endorectal coil were independently interpreted by two radiologists. A five-point subjective suspicion score (SSS) was assigned to all focal abnormalities (FAs). MR findings were then compared with whole-mount sections.
RESULTS: Readers identified 192-214/362 cancers, with 130-155 false positives. Detection rates for tumours of <0.5 cc (cm(3)), 0.5-2 cc and >2 cc were 33-45/155 (21-29 %), 15-19/35 (43-54 %) and 8-9/12 (67-75 %) for Gleason ≤6, 17/27 (63 %), 42-45/51 (82-88 %) and 34/35 (97 %) for Gleason 7 and 4/5 (80 %), 13/14 (93 %) and 28/28 (100 %) for Gleason ≥8 cancers respectively. At multivariate analysis, detection rates were influenced by tumour Gleason score, histological volume, histological architecture and location (P < 0.0001), but neither by field strength nor coils used for imaging. The SSS was a significant predictor of both malignancy of FAs (P < 0.005) and aggressiveness of tumours (P < 0.00001).
CONCLUSIONS: Detection rates were significantly influenced by tumour characteristics, but neither by field strength nor coils used for imaging. The SSS significantly stratified the risk of malignancy of FAs and aggressiveness of detected tumours. KEY POINTS: • Prostate cancer volume, Gleason score, architecture and location are MRI predictors of detection. • Field strength and coils used do not influence the tumour detection rate. • Multiparametric MRI is accurate for detecting aggressive tumours. • A subjective suspicion score can stratify the risk of malignancy and tumour aggressiveness.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23494494     DOI: 10.1007/s00330-013-2795-0

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  50 in total

1.  Consensus criteria for the use of magnetic resonance imaging in the diagnosis and staging of prostate cancer: not ready for routine use.

Authors:  Axel Heidenreich
Journal:  Eur Urol       Date:  2011-01-18       Impact factor: 20.096

Review 2.  Focal therapy in prostate cancer: modalities, findings and future considerations.

Authors:  Uri Lindner; John Trachtenberg; Nathan Lawrentschuk
Journal:  Nat Rev Urol       Date:  2010-09-14       Impact factor: 14.432

3.  Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy.

Authors:  T Y Chan; A W Partin; P C Walsh; J I Epstein
Journal:  Urology       Date:  2000-11-01       Impact factor: 2.649

4.  Is it possible to model the risk of malignancy of focal abnormalities found at prostate multiparametric MRI?

Authors:  Olivier Rouvière; Matthieu Papillard; Nicolas Girouin; Romain Boutier; Muriel Rabilloud; Benjamin Riche; Florence Mège-Lechevallier; Marc Colombel; Albert Gelet
Journal:  Eur Radiol       Date:  2012-01-07       Impact factor: 5.315

Review 5.  How good is MRI at detecting and characterising cancer within the prostate?

Authors:  Alexander P S Kirkham; Mark Emberton; Clare Allen
Journal:  Eur Urol       Date:  2006-06-30       Impact factor: 20.096

6.  MRI in the detection of prostate cancer: combined apparent diffusion coefficient, metabolite ratio, and vascular parameters.

Authors:  Sophie F Riches; Geoffrey S Payne; Veronica A Morgan; Samir Sandhu; Cyril Fisher; Michael Germuska; David J Collins; Alan Thompson; Nandita M deSouza
Journal:  AJR Am J Roentgenol       Date:  2009-12       Impact factor: 3.959

7.  Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal--pelvic phased-array coils.

Authors:  H Hricak; S White; D Vigneron; J Kurhanewicz; A Kosco; D Levin; J Weiss; P Narayan; P R Carroll
Journal:  Radiology       Date:  1994-12       Impact factor: 11.105

8.  Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy.

Authors:  Alexandre Ben Cheikh; Nicolas Girouin; Marc Colombel; Jean-Marie Maréchal; Albert Gelet; Alvine Bissery; Muriel Rabilloud; Denis Lyonnet; Olivier Rouvière
Journal:  Eur Radiol       Date:  2008-10-17       Impact factor: 5.315

9.  Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2--sparse versus dense cancers.

Authors:  Deanna L Langer; Theodorus H van der Kwast; Andrew J Evans; Laibao Sun; Martin J Yaffe; John Trachtenberg; Masoom A Haider
Journal:  Radiology       Date:  2008-12       Impact factor: 11.105

10.  ESUR prostate MR guidelines 2012.

Authors:  Jelle O Barentsz; Jonathan Richenberg; Richard Clements; Peter Choyke; Sadhna Verma; Geert Villeirs; Olivier Rouviere; Vibeke Logager; Jurgen J Fütterer
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315

View more
  66 in total

1.  Prostatic ductal adenocarcinoma: an aggressive tumour variant unrecognized on T2 weighted magnetic resonance imaging (MRI).

Authors:  Nicola Schieda; Niamh Coffey; Previn Gulavita; Omran Al-Dandan; Wael Shabana; Trevor A Flood
Journal:  Eur Radiol       Date:  2014-04-01       Impact factor: 5.315

2.  Inter-reader agreement of the ESUR score for prostate MRI using in-bore MRI-guided biopsies as the reference standard.

Authors:  L Schimmöller; M Quentin; C Arsov; R S Lanzman; A Hiester; R Rabenalt; G Antoch; P Albers; D Blondin
Journal:  Eur Radiol       Date:  2013-06-12       Impact factor: 5.315

3.  Multimodal Imaging in Focal Therapy Planning and Assessment in Primary Prostate Cancer.

Authors:  Hossein Jadvar
Journal:  Clin Transl Imaging       Date:  2017-04-10

Review 4.  [Prostate gland - what would urologists like to know from radiologists?]

Authors:  U B Liehr; D Baumunk; S Blaschke; F Fischbach; B Friebe; F König; A Lemke; P Mittelstädt; M Pech; M Porsch; J Ricke; D Schindele; S Siedentopf; J J Wendler; M Schostak
Journal:  Radiologe       Date:  2017-08       Impact factor: 0.635

5.  The detection of significant prostate cancer is correlated with the Prostate Imaging Reporting and Data System (PI-RADS) in MRI/transrectal ultrasound fusion biopsy.

Authors:  Hannes Cash; Andreas Maxeiner; Carsten Stephan; Thomas Fischer; Tahir Durmus; Josephine Holzmann; Patrick Asbach; Matthias Haas; Stefan Hinz; Jörg Neymeyer; Kurt Miller; Karsten Günzel; Carsten Kempkensteffen
Journal:  World J Urol       Date:  2015-08-21       Impact factor: 4.226

Review 6.  [Focal therapy for prostate cancer in Germany - 2014 status].

Authors:  A Roosen; R Ganzer; B Hadaschik; J Köllermann; A Blana; T Henkel; A-B Liehr; D Baumunk; S Machtens; G Salomon; L Sentker; U Witsch; K U Köhrmann; M Schostak
Journal:  Urologe A       Date:  2014-07       Impact factor: 0.639

Review 7.  [Treatment of localized prostate cancer with high-intensity focused ultrasound].

Authors:  D Baumunk; M Schostak
Journal:  Urologe A       Date:  2015-02       Impact factor: 0.639

8.  Comparison of quantitative apparent diffusion coefficient parameters with prostate imaging reporting and data system V2 assessment for detection of clinically significant peripheral zone prostate cancer.

Authors:  Elmira Hassanzadeh; Francesco Alessandrino; Olutayo I Olubiyi; Daniel I Glazer; Robert V Mulkern; Andriy Fedorov; Clare M Tempany; Fiona M Fennessy
Journal:  Abdom Radiol (NY)       Date:  2018-05

9.  Image quality and cancer visibility of T2-weighted magnetic resonance imaging of the prostate at 7 Tesla.

Authors:  E K Vos; M W Lagemaat; J O Barentsz; J J Fütterer; P Zámecnik; H Roozen; S Orzada; A K Bitz; M C Maas; T W J Scheenen
Journal:  Eur Radiol       Date:  2014-05-28       Impact factor: 5.315

10.  Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions.

Authors:  Anwar R Padhani; Jeffrey Weinreb; Andrew B Rosenkrantz; Geert Villeirs; Baris Turkbey; Jelle Barentsz
Journal:  Eur Urol       Date:  2018-06-13       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.